| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 10
| Issue : 6 | Page : 1735-1739 |
|
|
Decreased level of the anti-inflammatory adipokine, secreted frizzled-related protein 5, in patients with coronary artery disease
Aghdas Gharibi1, Parichehr Yaghmaei1, Gholam Basati2, Kourosh Soleimannejad3, Naser Abbasi2
1 Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2 Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Ilam, Iran
3 Department of Cardiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
Correspondence Address:
Gholam Basati
Biotechnology and Medicinal Plants Research Center, Ilam University of Medical Sciences, Banganjab St., Ilam
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ATMPH.ATMPH_621_17
|
|
|
Background: Secreted frizzled-related protein 5 (SFRP5) is an anti-inflammatory adipokine that excreted by adipose tissue and functions to modulate metabolic and inflammatory dysregulations. The exact contribution of SFRP5 toward coronary artery disease (CAD) is largely unclear. Objectives: In the current study, the potential role of SFRP5, by particular focusing on its anti-inflammatory effects, was sought in CAD. Patients and Methods: Serum levels of SFRP5 and the inflammatory biomarkers, oxidized low-density lipoprotein (Ox-LDL), and high-sensitivity C-reactive protein (hsCRP), were measured in 40 CAD patients and 40 controls who were identified based on coronary angiography examinations. The status of CAD severity (in accord with Gensini score) and traditional CAD risk factors were also determined. Association of SFRP5 with Ox-LDL, hsCRP, CAD severity, and traditional CAD risk factors was analyzed. Results: Serum SFRP5 level in CAD patients was significantly decreased compared to controls (28.60 ng/mL [25.67–34.58] vs. 39.92 ng/mL [32.82-49.91], P = 0.000). The correlation of serum SFRP5 level with hsCRP, Ox-LDL, body mass index, and Gensini score was reveal to be significant and negative (P < 0.05). Serum SFRP5 level was independently and inversely associated with CAD (odds ratio, 0.28 [95% confidence interval, 0.11–0.56], P = 0.001) and differentiated between CAD patients and controls (P = 0.01). Conclusions: Decreased level of serum SFRP5 is associated with CAD, highlighting its implication in CAD. It may also be a clinically useful biomarker for CAD.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
